
Alessandro Hammond is a Stage III cancer survivor. On January 15, 2026, Alessandro went in for an innocuous lump, which turned out to be an aggressive tumor. Alessandro was rushed into emergency surgery. He used an early version of NxtCure to find a clinical trial that changed his treatment trajectory. He immediately underwent several rounds of chemotherapy (3x BEP). Now a Harvard and Yale MD-PhD cancer researcher, he founded NxtCure Labs to get the next generation of cancer drugs to patients faster.
Promising oncology drugs are being developed faster than ever, but testing them and getting FDA approval is the bottleneck. Cancer drug trials take over a decade, and only about 3% of cancer drugs that enter human trials are ever approved.
NxtCure is building digital twins for cancer drug development, from the animal study to the clinical trial:
Alongside the twins, AI agents take on routine trial work such as site selection, patient pre-screening, safety monitoring and data cleaning, and every critical call goes to a physician expert.
NxtCure Labs is looking to connect with preclinical and clinical-stage biotechs to run their trials, or CROs that are interested in licensing our digital twins.
Website and Demo: https://nxtcure.com
Contact: Superadmin@nxtcure.com
Book A Demo: https://calendly.com/superadmin-nxtcure/nxtcure-labs-demo